These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7914104)

  • 1. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia.
    Santana VM; Hurwitz CA; Blakley RL; Crom WR; Luo X; Roberts WM; Ribeiro R; Mahmoud H; Krance RA
    Blood; 1994 Aug; 84(4):1237-42. PubMed ID: 7914104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
    Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
    J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.
    Krance RA; Hurwitz CA; Head DR; Raimondi SC; Behm FG; Crews KR; Srivastava DK; Mahmoud H; Roberts WM; Tong X; Blakley RL; Ribeiro RC
    J Clin Oncol; 2001 Jun; 19(11):2804-11. PubMed ID: 11387351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia.
    Vahdat L; Wong ET; Wile MJ; Rosenblum M; Foley KM; Warrell RP
    Blood; 1994 Nov; 84(10):3429-34. PubMed ID: 7949097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine.
    Saven A; Piro LD; Lemon RH; Figueroa ML; Kosty M; Ellison DJ; Beutler E
    Cancer; 1994 Jun; 73(12):2953-63. PubMed ID: 7911068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
    Kearns CM; Blakley RL; Santana VM; Crom WR
    Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.
    Santana VM; Mirro J; Harwood FC; Cherrie J; Schell M; Kalwinsky D; Blakley RL
    J Clin Oncol; 1991 Mar; 9(3):416-22. PubMed ID: 1671875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia.
    Van Den Neste E; Martiat P; Mineur P; Delannoy A; Doyen C; Zenebergh A; Michaux JL; Ferrant A
    Ann Hematol; 1998 Jan; 76(1):19-23. PubMed ID: 9486920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
    Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
    Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemia.
    Gollard R; Miller WE; Piro LD; Saven A
    Leuk Lymphoma; 1997 Dec; 28(1-2):183-5. PubMed ID: 9498718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
    Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
    Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
    Crews KR; Gandhi V; Srivastava DK; Razzouk BI; Tong X; Behm FG; Plunkett W; Raimondi SC; Pui CH; Rubnitz JE; Stewart CF; Ribeiro RC
    J Clin Oncol; 2002 Oct; 20(20):4217-24. PubMed ID: 12377965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
    Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A
    Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purine nucleoside analogues in the treatment of myleoid leukemias.
    Robak T
    Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
    Gordon MS; Young ML; Tallman MS; Cripe LD; Bennett JM; Paietta E; Longo W; Gerad H; Mazza J; Rowe JM
    Leuk Res; 2000 Oct; 24(10):871-5. PubMed ID: 10996206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
    Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
    Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia.
    Hellmann A; Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Robak T
    Eur J Haematol; 1999 Jul; 63(1):35-41. PubMed ID: 10414453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
    Weiss GR; Kuhn JG; Rizzo J; Smith LS; Rodriguez GI; Eckardt JR; Burris HA; Fields S; VanDenBerg K; von Hoff DD
    Cancer Chemother Pharmacol; 1995; 35(5):397-402. PubMed ID: 7850921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
    Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.